New shot could clear eczema in teens – trial underway
NCT ID NCT07042126
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests a drug called 611 in 180 Chinese teenagers (ages 12–17) with moderate-to-severe atopic dermatitis (eczema). 611 is an antibody that blocks a key driver of allergic inflammation. Participants receive injections every two weeks for up to a year. The main goal is to see if 611 significantly improves skin clearance and reduces itch compared to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
611 (a lab-made antibody that blocks a protein involved in allergic inflammation)
What this could lead to
If successful, this could offer a new treatment option for Chinese adolescents with moderate-to-severe eczema, helping to clear skin and reduce itch.
What could go wrong
This is a Phase 3 trial, but results may not apply outside this population. Side effects from blocking IL-4Rα can include injection reactions and infections. The placebo group may also improve.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
RECRUITINGNanchang, Zhejiang, 310003, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Fourth Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGJinhua, Zhejiang, 322000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••